Response Genetics, Inc. Announces Contract With Blue Cross and Blue Shield of Illinois

Response Genetics, Inc. Announces Contract With Blue Cross and Blue Shield of

LOS ANGELES, July 8, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc.
(Nasdaq:RGDX), a company focused on the development and sale of molecular
diagnostic tests that help determine a patient's response to cancer therapy,
today announced that it has recently executed a provider contract with Blue
Cross and Blue Shield of Illinois. Blue Cross and Blue Shield of Illinois has
7.4 million members, most of whom are located in the State of Illinois.

With the execution of this agreement, oncologists and pathologists affiliated
with this health plan now have the ability to more easily offer Response
Genetics' suite of molecular predictive testing for their patients battling
lung, colon, gastric, and melanoma cancers. Response Genetics' tests provide
treating physicians with actionable information that help enable the best
therapy to be employed for each individual patient. The personalized medicine
inherent in Response Genetics' testing services brings with it a value
proposition that is expected to improve patient outcomes and as a result
enhance efficiencies in health care delivery.

The contract with this Blue Cross Blue Shield Association affiliate
complements Response Genetics' existing managed care network and gives the
CLIA-licensed lab access to millions of additional Blue Cross Blue
Shield-insured members located primarily in Illinois and the Midwestern United
States. Blue Cross and Blue Shield of Illinois is the oldest and largest
health plan based in Illinois.

About Blue Cross and Blue Shield of Illinois

Blue Cross and Blue Shield of Illinois ("BCBSIL"), a division of Health Care
Service Corporation, a Mutual Legal Reserve Company, is the largest health
insurance company in Illinois. Started in 1936, BCBSIL remains member owned
rather than publicly traded and is committed to promoting the health and
wellness of its members and its communities, fostering greater access to care,
and working to lower the overall cost of care while improving the health care
quality and patient outcomes.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical
laboratory focused on the development and sale of molecular diagnostic testing
services for cancer. The Company's technologies enable extraction and analysis
of genetic information derived from tumor cells stored as formalin-fixed and
paraffin-embedded specimens.The Company's principal customers include
oncologists and pathologists.In addition to diagnostic testing services, the
Company generates revenue from the sale of its proprietary analytical
pharmacogenomic testing services of clinical trial specimens to the
pharmaceutical industry.The Company's headquarters is located in Los Angeles,
California.For more information, please visit

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and
the statements of representatives of the Company related thereto contain or
may contain, among other things, certain forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and
uncertainties.Such statements may include, without limitation, statements
with respect to the Company's plans, objectives, projections, expectations and
intentions, such as the ability of the Company, to provide clinical testing
services to the medical community, to continue to strengthen and expand its
sales force, to continue to build its digital pathology initiative, to attract
and retain qualified management, to continue to strengthen marketing
capabilities, to expand the suite of ResponseDX® products, to continue to
provide clinical trial support to pharmaceutical clients, to enter into new
collaborations with pharmaceutical clients, to enter into areas of companion
diagnostics, to continue to execute on its business strategy and operations,
to continue to analyze cancer samples and the potential for using the results
of this research to develop diagnostic tests for cancer, the usefulness of
genetic information to tailor treatment to patients, and other statements
identified by words such as "project," "may," "could," "would," "should,"
"believe," "expect," "anticipate," "estimate," "intend," "plan" or similar

These statements are based upon the current beliefs and expectations of the
Company's management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the Securities Exchange
Commission.Actual results, including, without limitation, actual sales
results, if any, or the application of funds, may differ from those set forth
in the forward-looking statements.These forward-looking statements involve
certain risks and uncertainties that are subject to change based on various
factors (many of which are beyond the Company's control).The Company
undertakes no obligation to publicly update forward-looking statements,
whether because of new information, future events or otherwise, except as
required by law.

CONTACT: Investor Relations Contact:
         Peter Rahmer
         Trout Group
         Company Contact:
         Thomas A. Bologna
         Chairman & Chief Executive Officer

Response Genetics Logo
Press spacebar to pause and continue. Press esc to stop.